Switch from antipsychotic polypharmacy to monotherapy reduces side effects

Inpatients with schizophrenia who switched from antipsychotic polypharmacy to mono­therapy experienced significantly reduced side effects, including extrapyramidal symptoms and metabolic effects, an open‐label trial has found. The vast majority of patients in the study's switch group stopped taking a first‐generation antipsychotic and continued on their second‐­generation drug. Study results were published online Sept. 16, 2024, in Schizophrenia Research .